A Study to Investigate the Safety and Pharmacokinetics of a Single Dose of VH3810109 (Also Known as GSK3810109), Administered Either Subcutaneously (SC) With rHuPH20 or Intravenously (IV), in Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 23, 2022

Primary Completion Date

April 10, 2023

Study Completion Date

April 10, 2023

Conditions

HIV Infections

Interventions

BIOLOGICAL

VH3810109

VH3810109 was administered.

BIOLOGICAL

rHuPH20

rHuPH20 was administered.

Trial Locations (1)

GSK Investigational Site, Austin